| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/07/2012 | WO2012061537A3 Methods for treating hair loss disorders |
| 09/07/2012 | WO2012023033A3 Mch-i restricted epitopes containing non-natural amino acid residues |
| 09/07/2012 | WO2012007728A3 Method for producing toxoids using alpha - dicarbonyl compounds |
| 09/07/2012 | CA2828844A1 Combination vaccines with lower doses of antigen and/or adjuvant |
| 09/07/2012 | CA2828464A1 Antagonistic dr3 ligands |
| 09/07/2012 | CA2828401A1 Therapeutic cancer vaccine |
| 09/07/2012 | CA2828000A1 Bispecific binding agents |
| 09/07/2012 | CA2827799A1 Tumor necrosis factor-a humanized antibody |
| 09/07/2012 | CA2827581A1 Anti-il-6 receptor antibodies and methods of use |
| 09/07/2012 | CA2824095A1 Vaccination in elderly patients |
| 09/07/2012 | CA2824094A1 Vaccination in newborns and infants |
| 09/07/2012 | CA2820885A1 Novel modulators and methods of use |
| 09/06/2012 | US20120225928 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 09/06/2012 | US20120225482 Mammalian cx3c chemokine antibodies |
| 09/06/2012 | US20120225478 Anti-amyloid beta antibodies and their use |
| 09/06/2012 | US20120225125 Nanoparticles for Extravascular Administration |
| 09/06/2012 | US20120225114 Modifying Macrophage Phenotype for Treatment of Disease |
| 09/06/2012 | US20120225097 Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
| 09/06/2012 | US20120225094 Treatment of Sleep Disordered Breathing with Neurotoxin |
| 09/06/2012 | US20120225093 Abrogating HIV-1 Infection via Drug-Induced Reactivation of Apoptosis |
| 09/06/2012 | US20120225091 Modified live (jmso strain) haemophilus parasuis vaccine |
| 09/06/2012 | US20120225090 Methods for enhancing antigen-specific immune responses |
| 09/06/2012 | US20120225089 Novel conjugates, preparation thereof, and therapeutic use thereof |
| 09/06/2012 | US20120225088 Compositions and methods for treating cancer and other diseases |
| 09/06/2012 | US20120225087 Nicotine haptens, immunoconjugates and their uses |
| 09/06/2012 | US20120225086 Binding molecules to the human ox40 receptor |
| 09/06/2012 | US20120225085 Display of disulfide linked dimeric proteins in filamentous phage |
| 09/06/2012 | US20120225084 Klf family members regulate intrinsic axon regeneration ability |
| 09/06/2012 | US20120225083 Viral polypeptides and methods |
| 09/06/2012 | US20120225082 ADAM12 Inhibitors and Their Use Against Inflammation-Induced Fibrosis |
| 09/06/2012 | US20120225081 Vegf-binding molecules |
| 09/06/2012 | US20120225080 Human antibodies that bind the p40 subunit of human il-12/il-23 and uses therefor |
| 09/06/2012 | US20120225079 Immunizing composition for reducing streptococcal infections |
| 09/06/2012 | US20120225078 Immune system modulating composition |
| 09/06/2012 | US20120225077 Novel molecules of the card-related protein family and uses thereof |
| 09/06/2012 | US20120225076 Fra-1 target genes as drug targets for treating cancer |
| 09/06/2012 | US20120225075 Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
| 09/06/2012 | US20120225074 Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition |
| 09/06/2012 | US20120225073 Isolation and Use of Melanoma Cancer Stem Cells |
| 09/06/2012 | US20120225072 Stable formulations of immunoglobulin single variable domains and uses thereof |
| 09/06/2012 | US20120225071 Bivalent, bispecific antibodies |
| 09/06/2012 | US20120225070 Methods for treating progressive multiple sclerosis |
| 09/06/2012 | US20120225069 Use of a compound for reducing the biological effectiveness of il-6 |
| 09/06/2012 | US20120225068 Monoclonal antibodies as a medicament for the therapeutic and/or prophylactic treatment of swine-origin influenza a (h1n1) virus (s-oiv) infections |
| 09/06/2012 | US20120225067 Composition and Method for Mediating an Immune Response |
| 09/06/2012 | US20120225066 Therapeutic nuclease compositions and methods |
| 09/06/2012 | US20120225065 Anti-human il-21 monoclonal antibodies |
| 09/06/2012 | US20120225064 Sphingosine 1-Phosphate Antagonism |
| 09/06/2012 | US20120225063 Treatment response to anti-angiogenic therapies |
| 09/06/2012 | US20120225061 Tetrasubstituted cyclohexyl compounds as kinase inhibitors |
| 09/06/2012 | US20120225060 Anti-il-6 receptor antibodies and methods of use |
| 09/06/2012 | US20120225059 Novel Agents and Uses Thereof |
| 09/06/2012 | US20120225058 Novel immunoglobulin insertions, deletions, and substitutions |
| 09/06/2012 | US20120225057 Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| 09/06/2012 | US20120225056 Methods and compositions for treating complement-associated disorders |
| 09/06/2012 | US20120225055 Antigen binding proteins |
| 09/06/2012 | US20120225043 Enhancement of Immune Responses By 4-1BB-Binding Agents |
| 09/06/2012 | US20120225031 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders |
| 09/06/2012 | US20120225030 Uses of mammalian cytokine; related reagents |
| 09/06/2012 | US20120225021 Stable colloidal gold nanoparticles with controllable surface modification and functionalization |
| 09/06/2012 | US20120225014 Antibodies to cd40 |
| 09/06/2012 | US20120225013 Anti-mesothelin antibodies and immunoconjugates |
| 09/06/2012 | US20120225012 Composition for hard tissue repair |
| 09/06/2012 | US20120225011 Glassy compositions |
| 09/05/2012 | EP2495327A2 Methods and compositions to treat and detect misfolded-SOD1 mediated diseases |
| 09/05/2012 | EP2495326A2 Materials and methods for respiratory disease control in canines |
| 09/05/2012 | EP2495325A2 Dna vaccine against virus of yellow fever |
| 09/05/2012 | EP2495324A2 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 09/05/2012 | EP2495319A1 INTEGRIN alpha8beta1-SPECIFIC MONOCLONAL ANTIBODY |
| 09/05/2012 | EP2495314A1 Novel vaccine composition |
| 09/05/2012 | EP2495257A2 Dual variable domain immunoglobulin and uses thereof |
| 09/05/2012 | EP2495256A1 Antibody having activity of inhibiting infection with hepatitis c virus (hcv) and use of same |
| 09/05/2012 | EP2495252A2 Soluble forms of hendra and nipah virus G glycoprotein |
| 09/05/2012 | EP2494988A1 Antagonist antibodies against EPHB3 |
| 09/05/2012 | EP2494987A1 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
| 09/05/2012 | EP2494986A1 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
| 09/05/2012 | EP2494985A1 Zona pellucida binding peptides, expression vectors, compositions, and methods for species-specific immunocontraception of animals |
| 09/05/2012 | EP2494984A1 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses |
| 09/05/2012 | EP2494980A2 Medical utility of glycans |
| 09/05/2012 | EP2493930A1 Compositions and methods for treating inflammatory disorders |
| 09/05/2012 | EP2493925A1 Human il-23 antigen binding proteins |
| 09/05/2012 | EP2493924A2 Dual variable domain immunoglobulins and uses thereof |
| 09/05/2012 | EP2493911A2 Peptide compositions and methods for inhibiting herpesvirus infection |
| 09/05/2012 | EP2493507A2 Ax213 and ax132 pcsk9 antagonists and variants |
| 09/05/2012 | EP2493506A2 Il-17a antagonists |
| 09/05/2012 | EP2493505A1 Ax1 and ax189 pcsk9 antagonists and variants |
| 09/05/2012 | EP2493504A1 Stable anti-tnfr1 polypeptides, antibody variable domains&antagonists |
| 09/05/2012 | EP2493503A1 Dosage regimen for administering a cd19xcd3 bispecific antibody |
| 09/05/2012 | EP2493502A1 Process for preparing an influenza seed virus for vaccine manufacture |
| 09/05/2012 | EP2493501A1 Process for producing influenza vaccine |
| 09/05/2012 | EP2493500A2 Pharmaceutical composition for the treatment and prevention of a rhinovirus infection |
| 09/05/2012 | EP2493499A1 Modified meningococcal fhbp polypeptides |
| 09/05/2012 | EP2493498A1 Purification of staphylococcus aureus type 5 and type 8 capsular saccharides |
| 09/05/2012 | EP2493486A1 Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| 09/05/2012 | EP2493464A1 Methylsulfonylmethane (msm) for treatment of drug resistant microorganisms |
| 09/05/2012 | CN1961001B Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins |
| 09/05/2012 | CN1922209B Anti-ab antibody |
| 09/05/2012 | CN1905897B Antagonist anti-CD40 monoclonal antibodies and methods for their use |
| 09/05/2012 | CN1859923B Optimized expression of hpv 45 l1 in yeast |
| 09/05/2012 | CN1814757B Novel CpGDNA adjuvant, its preparing method and vaccine containing same |